Telomir Pharmaceuticals, Inc. Proceeds from Secured Lines of Credit
Telomir Pharmaceuticals, Inc. (TELO) reported Proceeds from Secured Lines of Credit of $5.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromSecuredLinesOfCredit · last filed 2024-11-12
- 2024-09-30: Proceeds from Secured Lines of Credit 9 month $5.00M.
| Period end | Proceeds from Secured Lines of Credit 9 month |
|---|---|
| 2024-09-30 | $5.00M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |